The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

Epithelial‐to‐mesenchymal transition (EMT) is implicated in a wide array of malignant
behaviors of cancers, including proliferation, invasion, and metastasis. Most notably, previou …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

Transforming growth factor (TGF)-β is an evolutionarily conserved pleiotropic factor that
regulates a myriad of biological processes including development, tissue regeneration …

Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …

Over the last decade, important clinical benefits have been achieved in cancer patients by
using drug-targeting strategies. Nevertheless, drug resistance is still a major problem in …

Cancer metastasis and therapy resistance are the major unsolved clinical challenges, and
account for nearly all cancer-related deaths. Both metastasis and therapy resistance are …

Chemoresistant metastatic relapse of minimal residual disease plays a significant role for
poor prognosis of cancer. Growing evidence supports a critical role of cancer stem cell …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

Purpose: Epithelial–mesenchymal transition (EMT) has been associated with metastatic
spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust …